Related references
Note: Only part of the references are listed.Cancer metabolism: a therapeutic perspective
Ubaldo E. Martinez-Outschoorn et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
High resolution mass spectrometry based method applicable for a wide range of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors in blood serum including intermediates and products of the cholesterol biosynthetic pathway
Vit Kosek et al.
JOURNAL OF CHROMATOGRAPHY A (2017)
Variability in statin-induced changes in gene expression profiles of pancreatic cancer
Helena Gbelcova et al.
SCIENTIFIC REPORTS (2017)
Synergistic Antiproliferative Effects of Zoledronic Acid and Fluvastatin on Human Pancreatic Cancer Cell Lines: An in Vitro Study
Mahitab Elsayed et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2016)
HMGCR is up-regulated in gastric cancer and promotes the growth and migration of the cancer cells
Li Chushi et al.
GENE (2016)
Targeting mutant p53 through the mevalonate pathway
William Freed-Pastor et al.
NATURE CELL BIOLOGY (2016)
The interplay between cell signalling and the mevalonate pathway in cancer
Peter J. Mullen et al.
NATURE REVIEWS CANCER (2016)
A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer
S. H. Lim et al.
BRITISH JOURNAL OF CANCER (2015)
PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions
Jonathan A. Ledermann et al.
BRITISH JOURNAL OF CANCER (2015)
Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients
J. M. Baas et al.
INVESTIGATIONAL NEW DRUGS (2015)
Impact of statins on risk and survival of ovarian cancer
Muhammad Shahzeb Khan et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2015)
p53 regulates the mevalonate pathway in human glioblastoma multiforme
C. Laezza et al.
CELL DEATH & DISEASE (2015)
Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients
Emma Gustbee et al.
BMC CLINICAL PATHOLOGY (2015)
Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells
Carolyn A. Goard et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells
P. Jiang et al.
BRITISH JOURNAL OF CANCER (2014)
Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients
Jung Yong Hong et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome
Erik Bengtsson et al.
DIAGNOSTIC PATHOLOGY (2014)
Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: A double-blind randomised phase 3 study
Seung Tae Kim et al.
EUROPEAN JOURNAL OF CANCER (2014)
Dietary supplementation with geranylgeraniol suppresses lipopolysaccharide-induced inflammation via inhibition of nuclear factor-κB activation in rats
Puspo E. Giriwono et al.
EUROPEAN JOURNAL OF NUTRITION (2013)
Preclinical evaluation of statins as a treatment for ovarian cancer
Elizabeth Robinson et al.
GYNECOLOGIC ONCOLOGY (2013)
Evaluating cell lines as tumour models by comparison of genomic profiles
Silvia Domcke et al.
NATURE COMMUNICATIONS (2013)
Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer
Patrizia Gazzerro et al.
PHARMACOLOGICAL REVIEWS (2012)
A Phase 2 Study of Irinotecan, Cisplatin, and Simvastatin for Untreated Extensive-disease Small Cell Lung Cancer
Ji-Youn Han et al.
CANCER (2011)
Polished rice as natural sources of cancer-preventing geranylgeranoic acid
Takashi Muraguchi et al.
JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Rethinking ovarian cancer: recommendations for improving outcomes
Sebastian Vaughan et al.
NATURE REVIEWS CANCER (2011)
Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer
Donal J. Brennan et al.
BMC CANCER (2010)
Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer
Elisabeth R. Garwood et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells
Susanne Vidot et al.
CELLULAR SIGNALLING (2010)
Dysregulation of the mevalonate pathway promotes transformation
James W. Clendening et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study
Jeeyun Lee et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma
T. E. Sondergaard et al.
HEMATOLOGICAL ONCOLOGY (2009)
Chromatography-tandem mass spectrometry method for the simultaneous quantitation of metoprolol succinate and simvastatin in human plasma
P. Senthamil Selvan et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2009)
Analysis of p53 mutation status in human cancer cell lines - A paradigm for cell line cross-contamination
Hanna Berglind et al.
CANCER BIOLOGY & THERAPY (2008)
Wax ester fraction of edible oils: Analysis by on-line LC-GC-MS and GC x GC-FID
Maurus Biedermann et al.
EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY (2008)
Transient ectopic expression as a method to detect genes conferring drug resistance
James Witham et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Solid-phase extraction and liquid chromatography/tandem mass spectrometry assay for the determination of pitavastatin in human plasma and urine for application to Phase I clinical pharmacokinetic studies
Bin Di et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2008)
Inhibition of geranylgeranyl diphosphate synthase induces apoptosis through multiple mechanisms and displays synergy with inhibition of other isoprenoid biosynthetic enzymes
Amel Dudakovic et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Synergistic antimyeloma effects of zoledronate and simvastatin
Ralf Schmidmaier et al.
ANTI-CANCER DRUGS (2006)
Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies
SA Holstein et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Zoledronic acid (Zometa (R)) enhances the cytotoxic effect of gemcitabine and fluvastatin: In vitro isobologram studies with conventional and nonconventional cytotoxic agents
DR Budman et al.
ONCOLOGY (2006)
A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix
JJ Knox et al.
EUROPEAN JOURNAL OF CANCER (2005)
Analysis of the wax ester fraction of olive oil and sunflower oil by gas chromatography and gas chromatography-mass spectrometry
B Reiter et al.
JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY (2001)
Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma
WS Kim et al.
INVESTIGATIONAL NEW DRUGS (2001)
Share Paper
